According to the company, the new facility will be used to support ongoing research into new applications of the company’s platform technology.
The new laboratory space was included in Amicus’s operating plan and budget for 2008 as part of increased investment in research beyond the lysosomal storage disorders. Amicus expects to begin occupying the space immediately.
John Crowley, president and CEO of Amicus, said: “The focus of our research efforts in San Diego will be to assess new chaperone applications in diseases with high unmet medical needs and larger patient populations particularly in the areas of neurodegenerative and metabolic disorders. This small scale facility will complement our core R&D activities in New Jersey.”